Biology Insights

What Are the Side Effects of Hormone Therapy for Breast Cancer?

Explore the health impacts of reducing estrogen with hormone therapy for breast cancer, from immediate physical changes to long-term considerations.

By Raquel Ortega

Hormone therapy for breast cancer works by starving tumors of the estrogen they need to grow, and the side effects flow directly from that same estrogen deprivation. The most common complaints include hot flashes, joint and muscle pain, bone thinning, vaginal dryness, fatigue, mood changes, and weight gain. Because these drugs are typically taken for five to ten years, the side effects are not brief inconveniences but ongoing realities that shape daily life. The specific profile depends on which drug you take, whether you were premenopausal or postmenopausal when you started, and even your individual genetics.

Two Drug Classes, Two Sets of Trade-Offs

Hormone therapy for breast cancer falls into two main camps. Tamoxifen blocks the estrogen receptor on cancer cells, preventing estrogen from sending its growth signal. Aromatase inhibitors, on the other hand, slash estrogen levels throughout the body by blocking the enzyme that produces it in postmenopausal women. Both strategies reduce cancer recurrence substantially, but because they disrupt estrogen through different mechanisms, they create somewhat different side-effect profiles. Tamoxifen carries unique risks to the uterus and blood-clotting system, while aromatase inhibitors are harder on bones and joints. Many side effects, though, overlap between the two.

Hot Flashes

Hot flashes are the side effect people hear about first, and for good reason. In clinical trials, roughly a third to over 40 percent of women on either tamoxifen or aromatase inhibitors reported them. A study of breast cancer survivors found that about half had experienced at least one hot flash in the past 24 hours. Among those who did have them in a given week, the average was about three to four episodes per day. That said, most survivors described their hot flashes as either absent or mild.

Tamoxifen tends to produce slightly more hot flashes than aromatase inhibitors in head-to-head trials, though the gap is modest. In the large ATAC trial, about 41 percent of women on tamoxifen reported hot flashes compared with 36 percent on anastrozole. Similar patterns appeared in trials of letrozole and exemestane. What matters more than the averages, though, is that some women are hit much harder than others. Predictors of worse hot flashes include a history of hormone replacement therapy, being pushed into early menopause by treatment, obesity, and smoking.

Hot flashes are more than a comfort issue. Research has linked severe hot flashes to higher rates of treatment discontinuation, which in turn can worsen breast cancer outcomes. They also tend to improve over time, which is worth knowing if the first few months feel overwhelming.

Joint Pain and Musculoskeletal Symptoms

If hot flashes are the most talked about side effect, joint and muscle pain may be the most disruptive, especially with aromatase inhibitors. The pain often shows up in the hands, wrists, knees, and feet. It can feel like morning stiffness that takes a while to loosen, or like a persistent ache that makes it harder to grip things or climb stairs. A systematic review found that the root cause is estrogen deprivation itself, which affects immune function, bone turnover, and pain sensitivity. Imaging studies have identified subtle inflammation in tendons and their surrounding sheaths, even in women who have no visible swelling.

This is one of the leading reasons women stop taking aromatase inhibitors. The stiffness and aching typically start within the first few months and, for some women, never fully resolve while they remain on the drug. Switching to a different aromatase inhibitor sometimes helps, since the three available drugs have slightly different chemical structures. Exercise, particularly resistance training and yoga, has shown modest benefit in some trials.

Bone Thinning and Fracture Risk

Estrogen plays a major role in maintaining bone density, so suppressing it comes at a cost. Aromatase inhibitors lower circulating estrogen to near-undetectable levels in postmenopausal women, which accelerates bone loss. That translates into real fracture risk: a study comparing aromatase inhibitor users to tamoxifen users found that aromatase inhibitors raised fracture risk by roughly 40 percent.

Tamoxifen, interestingly, tends to be kinder to bones in postmenopausal women, where it has a mild bone-protective effect. The comparison flips in premenopausal women, where tamoxifen can also contribute to bone loss, especially when combined with ovarian suppression drugs. Bone density monitoring is standard practice for women on aromatase inhibitors, and bisphosphonate medications are often prescribed alongside the cancer treatment to slow bone loss. Vitamin D and calcium supplementation are also commonly recommended, though they are not sufficient on their own to counteract the drug effect.

Blood Clots and Cardiovascular Effects

Tamoxifen carries a well-documented risk of blood clots, specifically deep vein thrombosis and pulmonary embolism. A Danish population-based study found that the five-year risk of these events was about 1.2 percent in women receiving tamoxifen compared with 0.5 percent in those who were not. The risk was highest in the first two years of use. Another study found the relative risk of venous clots was roughly sevenfold higher during active tamoxifen use compared with never or past use. Older women with breast cancer who had ever used tamoxifen showed roughly double the odds of deep vein thrombosis or pulmonary embolism compared with women who had never used it.

Aromatase inhibitors do not carry the same clotting risk as tamoxifen, but they have their own cardiovascular wrinkle: some may worsen cholesterol levels. Data on this is mixed. Anastrozole may have little effect on lipids, while letrozole has been linked to unfavorable changes in some trials. Exemestane may be slightly better in this regard. Despite these lipid shifts, short-term trial data have not shown a clear increase in heart attacks or strokes with aromatase inhibitors.

Effects on the Uterus

Tamoxifen is a selective estrogen receptor modulator, meaning it blocks estrogen in breast tissue but acts like estrogen in certain other tissues, including the uterine lining. This dual nature is why tamoxifen raises the risk of endometrial polyps, thickening of the uterine lining, and uterine cancer. A large study of premenopausal women found that tamoxifen use roughly quadrupled the risk of endometrial polyps and raised the risk of endometrial hyperplasia by about fivefold. A separate study in young women with breast cancer found similar magnitudes: the hazard ratio for endometrial polyps was about four times higher, and for endometrial hyperplasia more than five times higher, in tamoxifen users. The risk climbed with longer duration of use.

Aromatase inhibitors do not have this effect, since they do not mimic estrogen. Women taking tamoxifen are typically advised to report any unusual vaginal bleeding promptly, and routine gynecological monitoring is standard during treatment.

Vaginal and Sexual Health

Vaginal dryness, itching, irritation, pain during intercourse, and urinary symptoms are all common with hormone therapy, especially aromatase inhibitors. These symptoms are collectively referred to as genitourinary syndrome of menopause by clinicians. Despite how widespread these problems are, they remain under-addressed in clinical practice. Many oncologists do not routinely ask about them, and many women are reluctant to bring them up.

Non-hormonal options such as vaginal moisturizers, lubricants, and dilators are usually the first line of management. An umbrella review of clinical guidelines found broad consensus supporting moisturizers, gels, and lubricants for vulvovaginal symptoms. Low-dose vaginal estrogen is sometimes considered for severe cases, though it remains controversial in the context of estrogen-sensitive breast cancer, and the decision involves weighing quality of life against theoretical recurrence risk.

Fatigue and Sleep Disruption

Fatigue is one of those side effects that does not get a dramatic-sounding name but quietly erodes quality of life. Anti-estrogen endocrine therapies are recognized as a risk factor for sleep disturbances and insomnia among breast cancer survivors. Part of this is driven by night sweats and hot flashes that fragment sleep, but the relationship goes beyond that; estrogen deprivation itself appears to affect sleep architecture. In premenopausal women receiving tamoxifen combined with ovarian function suppression, insomnia and sleep quality worsened within the first several months of starting hormone therapy.

The combination of fatigue and poor sleep is a major driver of treatment discontinuation. Exercise has shown some promise for managing both symptoms. A systematic review found that yoga and aerobic exercise could reduce fatigue in women on adjuvant hormone therapy, though the evidence was strongest for fatigue and weaker for sleep improvement specifically.

Mood, Anxiety, and Cognitive Effects

Mood disturbances, anxiety, and mental fogginess are reported by many women on hormone therapy, although teasing apart drug effects from the psychological burden of a cancer diagnosis is genuinely difficult. Mood changes, somnolence, anxiety, and fatigue have been documented among women on anastrozole specifically. One small study found that breast cancer survivors starting aromatase inhibitors had higher anxiety and depression scores than healthy controls at baseline. After six months of treatment, however, those symptoms actually improved, along with perceived quality of life. That finding suggests the emotional disruption some women feel early in treatment may be partly a reaction to diagnosis and initial adjustment rather than purely drug-driven.

Cognitive effects are a separate concern. An umbrella review of systematic reviews found that endocrine therapy was associated with impairments in memory, processing speed, executive functioning, and language. Among the drugs studied, tamoxifen was linked to worse cognitive performance than aromatase inhibitors, with verbal memory and processing speed particularly affected. These effects are typically subtle, showing up on neuropsychological testing rather than causing dramatic impairment, but they are real enough to affect daily functioning for some women.

Weight Gain and Body Composition

Many women gain weight during or after breast cancer treatment, and hormone therapy is one contributing factor alongside menopause itself and reduced physical activity. Weight gain typically ranges from about one to five kilograms and tends to involve gaining fat while losing lean muscle mass. Body composition shifts during endocrine therapy track closely with the changes seen during menopause, since both involve estrogen withdrawal. This shift matters beyond appearance, since increased body fat is itself associated with higher risk of cancer recurrence and other chronic diseases. Resistance exercise and dietary adjustments during treatment can help counteract these changes, though they are difficult to fully prevent.

Hair Thinning

Unlike the dramatic hair loss caused by chemotherapy, hormone therapy tends to cause a slow, diffuse thinning that may not become noticeable for months. In a study of over 100 patients with endocrine therapy-induced alopecia, the vast majority had mild hair loss, and the pattern resembled the gradual recession and thinning seen in female-pattern hair loss, with the frontal-temporal hairline and central scalp most affected. Alopecia developed on average about 17 months after starting treatment, though more than half of patients noticed it within the first year.

The emotional toll can be disproportionate to the clinical severity. Quality-of-life assessments showed that the emotional impact scored significantly higher than physical symptoms or functional limitations. Treatment options remain limited. The topic has not attracted much research compared with other side effects, and management advice is largely borrowed from the general female-pattern hair loss literature.

Eye Problems With Tamoxifen

Tamoxifen has a specific and lesser-known effect on the eyes. Long-term use (five years or more) is associated with an increased risk of cataracts. In one study, the relative risk of developing cataracts was about 1.7 for long-term tamoxifen users compared with non-users. Tamoxifen can also cause crystalline deposits on the retina and, more rarely, macular edema and corneal changes. These retinal effects were described primarily in case reports of patients on higher doses, but subtler changes can occur at standard doses over long periods. A controlled study found that posterior lens opacities were about four times more frequent in tamoxifen-treated patients than in controls. Regular eye exams are advisable for women on tamoxifen, especially those planning to take it for extended periods. Aromatase inhibitors are not associated with these eye effects.

Why Side Effects Vary So Much Between Individuals

Two women on the same dose of the same drug can have wildly different experiences, and genetics is one reason. Tamoxifen is a prodrug that must be converted by a liver enzyme called CYP2D6 into its active form. People carry different versions of the gene for this enzyme, which means some metabolize tamoxifen quickly and some slowly. Women whose genetics make them slow metabolizers tend to have lower levels of the active form of the drug, and early research found they had fewer hot flashes, consistent with less anti-estrogen activity. On the flip side, fast metabolizers showed fewer uterine changes associated with tamoxifen, likely because their bodies process and clear the drug more efficiently.

For aromatase inhibitors, genetic variants in genes involved in estrogen signaling, bone turnover, and pain sensitivity have been linked to who develops musculoskeletal symptoms. Vitamin D deficiency, which is common in cancer patients generally, is another modifiable factor that may worsen bone and joint symptoms. This kind of individual variability is part of why oncologists sometimes try switching between drugs or adjusting management strategies rather than simply telling patients to push through.

When Side Effects Threaten Adherence

Hormone therapy works best when taken consistently over years, but the side effects make that a genuinely difficult ask. In one study, about 12 percent of patients permanently stopped their endocrine therapy because of side effects. Another 21 percent seriously considered quitting, and about 8 percent took the medication inconsistently. The discontinuation rate was much higher during extended therapy beyond five years, reaching 24 percent, compared with about 6 percent during the initial five-year course. About 16 percent of patients switched to a different endocrine therapy due to intolerance. The problem matters because incomplete treatment is associated with worse cancer outcomes.

The implication is that side-effect management is not a luxury; it is part of effective cancer treatment. If a side effect is bad enough to make you consider stopping, that is a conversation to have with your oncology team rather than a decision to make alone. Switching drugs, adjusting doses, adding supportive medications, or incorporating lifestyle changes may be enough to keep you on an effective regimen.

Premenopausal Women and Ovarian Suppression

Premenopausal women with hormone-receptor-positive breast cancer are sometimes treated with ovarian suppression drugs (like goserelin or leuprorelin) alongside tamoxifen or an aromatase inhibitor. Ovarian suppression adds its own layer of side effects on top of the hormone therapy itself, essentially pushing a premenopausal woman into a medically induced menopause. Hot flashes, bone loss, vaginal dryness, and mood changes tend to be more intense in this group because the drop in estrogen is more abrupt and dramatic than what postmenopausal women experience.

For younger women, fertility is also a concern. Ovarian suppression during chemotherapy is sometimes used to protect the ovaries, and menstruation resumes in the vast majority of women within a year of completing chemo. One study found that over 94 percent of women who received either goserelin or leuprorelin resumed menstruation within 12 months, though markers of ovarian reserve still dropped significantly. Women planning to have children after treatment should discuss fertility preservation before starting hormone therapy, since the recommended five to ten years of treatment introduces significant delays.

Approaches to Managing Side Effects

A comprehensive review in The Lancet Oncology laid out the range of interventions available for managing hormone therapy side effects, spanning pharmacological approaches, non-drug strategies, and complementary methods across hot flashes, sexual dysfunction, weight gain, musculoskeletal symptoms, and fatigue. Here is what the evidence supports for the most common complaints:

The recurring theme across nearly every side effect is that exercise helps. It is not a cure-all, and telling someone who is fatigued and in pain to go exercise can feel dismissive. But the evidence, as imperfect as it is, consistently points to physical activity as the single most broadly helpful self-management strategy across hot flashes, joint symptoms, fatigue, mood, sleep, and weight control. Even moderate activity like regular walking appears beneficial.

Related Content

More in Cancer